Anti-TNF-α, particularly in the form of monoclonal antibodies, appears to be more effective, especially when patients have additional conditions like inflammatory bowel disease (IBD) or enthesitis-related arthritis. This evidence concerns the gene TNF and inflammatory bowel disease.